Abstract
Sympathetic nerve activity (SNA) is increased in both patients and experimental animals with renal failure. The kidney is a richly innervated organ and has both efferent and afferent nerves. Renal denervation shows protective effects against renal failure in both animals and humans. The underlying mechanisms include a decrease in blood pressure, a decrease in renal efferent SNA, a decrease in central SNA and sympathetic outflow, and downregulation of the reninangiotensin system. It has been demonstrated that re-innervation occurs within weeks after renal denervation in animals but that no functional re-innervation occurs in humans for over two years after denervation. Renal denervation might not be renal protective in some situations including bile duct ligation-induced renal failure and ischemia/reperfusion-induced acute kidney injury. Catheter-based renal denervation has been applied to patients with both early and end stage renal failure and the published results so far suggest that this procedure is safe and effective at decreasing blood pressure. The effectiveness of renal denervation in improving renal function in patients with renal failure needs to be further investigated.
Keywords: Acute kidney injury, chronic kidney disease, re-innervation, renal denervation, sympathetic nerve activity
Current Neurovascular Research
Title:Therapeutic Effects of Renal Denervation on Renal Failure
Volume: 10 Issue: 2
Author(s): Yutang Wang, Sai-Wang Seto and Jonathan Golledge
Affiliation:
Keywords: Acute kidney injury, chronic kidney disease, re-innervation, renal denervation, sympathetic nerve activity
Abstract: Sympathetic nerve activity (SNA) is increased in both patients and experimental animals with renal failure. The kidney is a richly innervated organ and has both efferent and afferent nerves. Renal denervation shows protective effects against renal failure in both animals and humans. The underlying mechanisms include a decrease in blood pressure, a decrease in renal efferent SNA, a decrease in central SNA and sympathetic outflow, and downregulation of the reninangiotensin system. It has been demonstrated that re-innervation occurs within weeks after renal denervation in animals but that no functional re-innervation occurs in humans for over two years after denervation. Renal denervation might not be renal protective in some situations including bile duct ligation-induced renal failure and ischemia/reperfusion-induced acute kidney injury. Catheter-based renal denervation has been applied to patients with both early and end stage renal failure and the published results so far suggest that this procedure is safe and effective at decreasing blood pressure. The effectiveness of renal denervation in improving renal function in patients with renal failure needs to be further investigated.
Export Options
About this article
Cite this article as:
Wang Yutang, Seto Sai-Wang and Golledge Jonathan, Therapeutic Effects of Renal Denervation on Renal Failure, Current Neurovascular Research 2013; 10 (2) . https://dx.doi.org/10.2174/1567202611310020010
DOI https://dx.doi.org/10.2174/1567202611310020010 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cardiac Calmodulin Kinase: A Potential Target for Drug Design
Current Medicinal Chemistry Relation Between Sleep Quality and Physical Activity in Chronic Heart Failure Patients
Recent Patents on Cardiovascular Drug Discovery The Small Heat Shock Protein HspB8: Role in Nervous System Physiology and Pathology
CNS & Neurological Disorders - Drug Targets Gene Therapy Strategies to Prevent Autoimmune Disorders
Current Gene Therapy Trends in Mitochondrial Therapeutics for Neurological Disease
Current Medicinal Chemistry Synergistic Effect of Inhibitors of MMPs and ROS-dependent Modifications of Contractile Proteins on Protection Hearts Subjected to Oxidative Stress
Current Pharmaceutical Design A PHACES Syndrome Unmasked by Propranolol Interruption in a Tetralogy of Fallot Patient: Case Report and Extensive Review on New Indications of Beta Blockers
Current Medicinal Chemistry The Anti-Inflammatory Potential of ACE2/Angiotensin-(1-7)/Mas Receptor Axis: Evidence from Basic and Clinical Research
Current Drug Targets Is a "Mitochondrial Psychiatry" in the Future? A Review
Current Psychiatry Reviews Pathophysiology of Cardiovascular Diseases and the Role of Vitamins, and Herbal Extracts in the Reduction of Cardiovascular Risks
Cardiovascular & Hematological Agents in Medicinal Chemistry Mitochondrial Biogenesis in Health and Disease. Molecular and Therapeutic Approaches
Current Pharmaceutical Design Targets and Patented Drugs for Chemotherapy of Chagas Disease in the Last 15 Years-Period
Recent Patents on Anti-Infective Drug Discovery Modulation of Cardiac Metabolism During Myocardial Ischemia
Current Pharmaceutical Design Cardiovascular Effects of Losartan and Its Relevant Clinical Application
Current Medicinal Chemistry Tapping into Mitochondria to Find Novel Targets for Diabetes Complications
Current Drug Targets Melatonin Causes Gene Expression in Aged Animals to Respond to Inflammatory Stimuli in a Manner Differing from that of Young Animals
Current Aging Science Renin--Angiotensin System Gene Polymorphism and Regression of Left Ventricular Hypertrophy in Hypertension
Current Pharmacogenomics Lights and Shadows on Monoamine Oxidase Inhibition in Neuroprotective Pharmacological Therapies
Current Topics in Medicinal Chemistry Imaging and Laboratory Biomarkers in Cardiovascular Disease
Current Pharmaceutical Design Intensive Glucose Control in Diabetics with an Acute Myocardial Infarction Does not Improve Mortality and Increases Risk of Hypoglycemia-A Meta-Regression Analysis
Current Vascular Pharmacology